Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Study Links Adenovirus Infection With a Rare Blood Clotting Disorder

Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.

11 Aug 2023

Study uncovers differences in how AstraZeneca and Pfizer COVID-19 vaccines affect the immune system

A new Australian study led by SAHMRI and Flinders University has uncovered fundamental differences in how the AstraZeneca and Pfizer COVID-19 vaccines impact the immune system.

23 Feb 2023

Study: Platelets likely to perform a protective function in AD

A new research paper was published on the cover of Aging entitled, "Immune-mediated platelet depletion augments Alzheimer's disease neuropathological hallmarks in APP-PS1 mice."

16 Feb 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Subcutaneous injection of teclistamab drug shows promise in treating aggressive multiple myeloma

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study being presented by Alfred L. Garfall, MD, an assistant professor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, at the annual American Society of Hematology & Exposition Meeting on Dec. 5 (abstract #180).

7 Dec 2020